New chemo cocktail aims to outperform standard care in colorectal cancer
NCT ID NCT07309289
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial tests whether a new combination of chemotherapy drugs (NALIRIFOX) plus targeted therapy works better than the standard FOLFOX regimen for people with metastatic colorectal cancer that has not been treated before. About 144 participants will receive one of the two treatments. The study aims to see if the new combo can delay cancer growth and improve response rates.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Irinotecan liposome, oxaliplatin, 5-FU, leucovorin, bevacizumab, cetuximab
What this could lead to
If successful, this could provide a more effective first-line treatment option for people with metastatic colorectal cancer, potentially improving survival and tumor shrinkage.
What could go wrong
This is a Phase 3 trial, but results may not show a significant benefit over standard therapy. Side effects from the combination chemotherapy and targeted drugs can be severe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER (CRC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Zhongshan Hospital
RECRUITINGShanghai, China
Contact Phone: •••-•••-••••